~20 awards were presented to companies for their exemplary performance at the 14th edition~

~Nominations for the 15th edition of the awards are now open ~

MUMBAI, India, Dec. 18, 2023 /PRNewswire/ — The 14th edition of Frost & Sullivan Sustainability 4.0 Awards was conducted on December 15, 2023, in a grand ceremony at Taj Bangalore, Bengaluru. The awards recognized companies embedding sustainability with economic value creation, creating value for all stakeholders, building a safer environment, and ensuring a stronger community. This year’s awards were presented across five major categories: Super Achievers Award – Sustainable Corporate of the Year Award, Leaders Award, Challengers Award, Believers Award and the Consistency Award.

Genpact India Pvt Limited, Gurugram walked away with the coveted Sustainable Corporate of the Year Award in the service sector along with the Consistency Platinum Award, while Cairn Oil & Gas, Vedanta Limited received the Sustainable Corporate of the Year Award in the manufacturing sector along with the Consistency Silver Award. Hindalco Industries Limited, Mumbai received the Sustainable Corporate of the Year Award – 1st Runner up and also the Consistency Silver Award. GHCL Limited was awarded the Challengers Award – Mega Large Business in the process sector.

The Sustainability 4.0 Awards program highlights the need for linkages between an organization’s strategy, governance, and financial performance and the social, environmental, and economic context within which it operates. This program enables businesses to make more logical and sustainable decisions that ensure long-term stakeholder value. It emphasizes the four pillars of sustainability: purpose, partnership, planet, and people.

Rahul Sharma, VP and Global Head, Digital Manufacturing & Sustainability, Frost & Sullivan, said, "Congratulations to all the winners for setting a pioneering example by seamlessly integrating their Digitalization initiatives with Sustainability strategies. Frost & Sullivan’s Sustainability 4.0 Awards establish a global framework for evaluating and recognizing companies that embody the triple bottom line and circular economy concepts. This recognition empowers businesses to discover innovative pathways for sustainable growth, ensuring enduring stakeholder value."

Adding further Mr. Sharma said, "In the dynamic corporate landscape, where Digitalization and Sustainability emerge as formidable market influencers, the Sustainability 4.0 Awards program evaluates how organizations seamlessly blend Digitalization initiatives with their Sustainability strategies and provide a clearer roadmap for what they need to do to be future-ready."

To know more about the awards and the methodology, please visit https://frost.ly/9e0
To schedule an interaction with our spokespersons, please email Aishwarya Nair at [email protected]

Recipients of the Sustainability 4.0 Awards 2023

Company Name

Award Title

SUPER ACHIEVERS AWARD

Genpact India Pvt Ltd

Sustainable Corporate of the Year Award – Service sector

Cairn Oil & Gas, Vedanta Limited

Sustainable Corporate of the Year Award – Manufacturing sector

Hindalco Industries Limited

Sustainable Corporate of the Year Award – 1st Runner up, Manufacturing sector

LEADERS AWARD

Genpact India Pvt Ltd

Leaders Award – Mega Large Business, Service Sector

Genpact India Pvt Ltd

Leaders Award – Mega Large Business, Service Sector

Genpact India Pvt Ltd

Leaders Award – Mega Large Business, Service Sector

Genpact India Pvt Ltd

Leaders Award – Mega Large Business, Service Sector

Genpact India Pvt Ltd

Leaders Award – Mega Large Business, Service Sector

Cairn Oil & Gas, Vedanta Limited (Rajasthan Asset)

Leaders Award – Mega Large Business, Process Sector

Cairn Oil & Gas, Vedanta Limited (Offshore – Ravva)

Leaders Award – Medium Business, Process Sector

Hindalco Industries Limited – Belagavi Works

Leaders Award – Mega Large Business, Metals Sector

Hindalco Industries Limited -Dahej Unit

Leaders Award – Mega Large Business, Metals Sector

Hindalco Industries Limited – Aditya Aluminium

Leaders Award – Mega Large Business, Metals Sector

Hindalco Industries Limited – Taloja Unit

Leaders Award – Large Business, Metals Sector

Hindalco Industries Limited – Mouda Unit

Leaders Award – Large Business, Metals Sector

CHALLENGERS AWARD

GHCL Limited

Challengers Award – Mega Large Business, Process Sector

BELIEVERS AWARD

Sajjan India Limited, Unit 1

Certificate of Merit – Believers Category

CONSISTENCY AWARDS

Genpact India Pvt Ltd

Consistency Platinum Award

Cairn Oil & Gas, Vedanta Limited

Consistency Silver Award

Hindalco Industries Limited

Consistency Silver Award

About Frost & Sullivan
For over six decades, Frost & Sullivan has helped build sustainable growth strategies for Fortune 1000 companies, governments, and investors. We apply actionable insights to navigate economic changes, identify disruptive technologies, and formulate new business models to create a stream of innovative growth opportunities that drive future success.

Media Contacts:-
For Frost & Sullivan:
Aishwarya Nair, Corporate Communications – South Asia
M: +91 9599021706
E: [email protected]
https://frost.ly/9hk 

Twitter: @Frost_Sullivan & @FrostSullivanIN (Event Hashtag: #SustainabilityAwards2023)
LinkedIn: (17) Frost & Sullivan India: My Company | LinkedIn 

Source : Frost & Sullivan Unveils Champions of Sustainable Excellence in the 2023 Sustainability 4.0 Awards

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

BEIJING and PARIS, Dec. 18, 2023 /PRNewswire/ — The 2023 International Genetically Engineered Machine Competition (iGEM), the global synthetic biology competition, concluded on November 5, 2023. Over 7,000 students from high schools and universities, organized into more than 400 teams worldwide, participated in this prestigious event. Among them, the Sun Yat-sen University Software Team (iGEM 2023 SYSU-Software), sponsored by Tsingke, achieved the IGEM GOLD MEDAL for their project "BioRocket: Systematic Discovery of Novel Protein Delivery Systems in Massive Prokaryotic Genomes."

The project focused on extracellular Contractile Injection Systems (eCISs), syringe-like protein complexes capable of injecting proteins into cells. Despite their potential as programmable protein delivery tools, only a limited number of eCISs have been characterized to date.

The iGEM 2023 SYSU-Software team developed the BioRocket platform to systematically explore eCISs within prokaryotic genomes using machine learning and structural computation. They also conducted high-throughput predictions of programmable targeting regions within eCISs. The project yielded impressive results, as BioRocket explored over 80,000 prokaryotic organisms, identifying 5,524 novel eCISs. Subsequent wet lab experiments were conducted to validate these novel eCISs identified by BioRocket.

Tsingke played a crucial role by leveraging its technical expertise, providing support, and assisting the team in completing related research on potential EATs genes. The company also verified the identified genes’ role as eCIS effector genes.

We aspire that our backing of iGEM 2023 SYSU-Software will inspire more individuals to commit themselves to the research of synthetic biology, contributing to the advancement of this industry.

About iGEM

The iGEM competition is an internationally renowned academic competition in the field of synthetic biology. It was initiated by the Massachusetts Institute of Technology (MIT) in the United States in 2003. It is a comprehensive international competition that revolves around synthetic biology and integrates various disciplines such as life sciences, mathematics, engineering, information science, and art design. The competition has gained widespread attention and special coverage from academic journals such as Nature, Science, Scientific American, The Economist, as well as media outlets like the BBC.

About Tsingke

Tsingke’s Gene Factory integrates in-house production of synthetic raw materials and related equipment, and establishes an independent factory-style service model covering the entire nucleic acid synthesis industrial chain.

By continuously researching and upgrading our synthesizers and synthetic materials for oligo production, our gene factory ensures the production of highly accurate oligos. This, in turn, guarantees stable and efficient gene synthesis with timely delivery. The plasmids Tsingke construct undergo NGS and Sanger sequencing validation to ensure 100% sequence accuracy.

Source : Tsingke Congratulates iGEM 2023 SYSU-Software on Winning GOLD MEDAL for BioRocket Project

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

GERMANTOWN, Md and GUANGZHOU, China, Dec. 18, 2023 /PRNewswire/ — Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced that, its subsidiary RNAimmune, Inc. ("RNAimmune"), a leading biotech company specializing in mRNA-based vaccines and therapeutics, has obtained a green light from the U.S. Food and Drug Administration (FDA) to proceed with its Investigational New Drug application for Phase I clinical trials of RV-1770, an mRNA vaccine targeting the human Respiratory Syncytial Virus (RSV).

RNAimmune will begin a Phase I clinical study to assess the safety and tolerance of RV-1770, a combination of an mRNA-based vaccine with a proprietary lipid nanoparticle formulation, aimed at preventing RSV infection in adults. Healthy volunteers between the ages of 18–49 and an older adult group aged 60–79 will receive a single dose of RV-1770 intramuscularly, using one of three dosage levels: 50 μg, 100 μg, or 200 μg. The study plans to recruit a total of 162 participants divided into two cohorts of younger and older adults with 81 each. All participants will undergo a 12-month post-vaccination monitoring for evaluation of RV-1770’s safety and immunogenicity.

RV-1770 is an innovative mRNA-based vaccine formulation with a unique AI-enhanced design using the sequence of the recent RSV clinical isolate. It demonstrated immunogenic responses and neutralization against both type A and B strains of RSV in preclinical cotton rat studies. "The IND clearance from the FDA represents a significant leap forward in our mission to provide a safe and effective solution against RSV infection and its profound impact on human health," stated Dr. Dong Shen, President and Chief Executive Officer of RNAimmune. "As we embark on clinical trials aimed at assessing the safety and efficacy of RV-1770, this achievement underscores the potential of RNAimmune’s mRNA technology platform in the battle against RSV and the prevention of associated respiratory diseases.

Dr. Patrick Lu, Chairman of the board of directors of RNAimmune, commented: "RV-1770 has a unique mRNA sequence design with a proprietary nanoparticle formulation that has already shown superb preclinical safety and efficacy. These results clearly demonstrate the strength of RNAimmune’s scientific team in quickly executing on its second vaccine program to move into clinical stage, working effectively with the company’s regulatory team and the FDA."

Dr. Dewan Zeng, Chief Executive Officer of Zhejiang Innoforce Pharmaceuticals Co., Ltd., the CDMO partner of the RV-1770 project, added: "We sincerely congratulate our partner, RNAimmune, on the FDA clearance of this IND application, and we are honored to be a partner in this innovative journey. We aim to leverage our cutting-edge technologies in ATMP manufacturing to help our partners to bring more effective ATMP to patients worldwide."

About Respiratory Syncytial Virus 
RSV is a major cause of hospitalizations due to pneumonia and bronchiolitis. Substantial morbidity and socioeconomic burden are associated with RSV infection worldwide. Populations with higher susceptibility to developing severe RSV include premature infants, children with chronic lung disease of prematurity or congenital heart disease, elderly individuals aged > 65 years, and immunocompromised individuals. In the pediatric population, RSV can lead to long-term sequelae such as wheezing and asthma, which are associated with increased health care costs and reduced quality of life. Treatment for RSV is mainly supportive, and general preventive measures such as good hygiene and isolation are highly recommended. Despite being a significant public health concern, the U.S. has only two approved RSV vaccines, and there is no approved RSV vaccine in China. RNAimmune’s RSV mRNA vaccine aims to address this unmet medical need by leveraging messenger RNA technology.

About RNAimmune, Inc.
RNAimmune is a pioneering biotech company dedicated to developing mRNA-based therapeutics and vaccines. With its global headquarters in Germantown, Maryland, USA, and a China headquarters in International BioIsland, Guangzhou, RNAimmune aims to address unmet medical needs by harnessing messenger RNA technology to create innovative solutions for infectious diseases, cancer, and other health challenges. RNAimmune holds a global exclusive right to the proprietary Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery from Sirnaomics. Additionally, RNAimmune possesses various independent proprietary R&D platforms, including artificial intelligence and directed neoantigen prediction, ALEPVA algorithm for nucleic acid sequence design, next-gen lipid nanoparticle (LNP) carrier systems, circular RNA, and self-amplify mRNA platforms. RNAimmune’s diverse pipeline includes vaccines for infectious diseases (RSV, COVID-19, influenza, HSV, etc.) and cancer vaccines (RAS, NY-ESO-1), along with mRNA-encoded antibodies. RNAimmune has achieved significant potential and is a leader in the field of mRNA vaccines and therapeutics. For more information about RNAimmune and its RSV mRNA vaccine development, please visit www.rnaimmune.com.

About Sirnaomics (stock code: 2257)
Sirnaomics is an RNA therapeutics biopharmaceutical company that focuses on the discovery and development of innovative drugs for indications with unmet medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAhead™, Sirnaomics has established an enriched drug candidate pipeline. STP122G, which represents the first drug candidate utilizing the Company’s GalAhead™ technology, is currently in Phase I development. The Company has also had multiple successes with oncology applications through its clinical programs for STP705 and STP707. With the establishment of the Group’s manufacturing facility in China, Sirnaomics is undergoing a transition from a biotech company to a biopharma corporation. Learn more at: www.sirnaomics.com .

Source : RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

KUALA LUMPUR, Malaysia, Dec. 18, 2023 /PRNewswire/ — The inaugural "ShangHai Honourable Women Entrepreneur Business Award 2023 (SHE 2023)," hosted by ShangHai Business Media took place at the prestigious EQ Hotel in Kuala Lumpur. The event witnessed the glorious moments of Malaysian women entrepreneurs.

Group photo of heavyweight guests, from left 5th, Y.B Lim Yiwei, Y.M. Tunku Dato’ Mu’tamir Tunku Tan Sri Mohamed, Y.Bhg Datin Paulene Tunku Mutamir

Female entrepreneurs play a crucial role and make significant contributions to building sustainable economic development, the "SHE 2023" aims to commend the outstanding achievements and dedication of women entrepreneurs in the business world. Guided by the principle of "Supporting Women, Building Futures," the awards emphasize ESG principles, inspiring more women to enter the business arena and pursue professional success, creating a gender-equal business environment.

As Malaysia’s most representative women entrepreneurs award, the "SHE 2023" has invited ten of Malaysia’s most authoritative women entrepreneurs to serve as professional judges, carefully selecting women entrepreneurs who meet the criteria and standards. The esteemed judges include Datin Dr. Cherlin Cheah, CEO of ShangHai Media Sdn Bhd; National Deputy President of SME Malaysia, Datin Dorph Peng; President of Malaysia Branding Association, Datin Winnie Loo; CEO of Sunway Education Group, Prof. Dato Dr. Elizabeth Lee; Executive Director of Ogawa Berhad, Datuk Lim Mee Ling; COO of Big Tree and Media Prima OMNiA; Chief Editor of Nan Yang Siang Pau, Ms Evie Loh; Chief of MRCA Women Division, Dato Winnie Lim; Chairman of MCAH Women Division, Datuk Ada Poon and Chairwomen of BNC Women Division, Dr Coco Wong. As titans in the business world, these ten judges are not only pillars in their respective fields but also role models for many entrepreneurs.

The SHE 2023 cordially invites the Member of Malaysian Institute of Chartered Secretaries and Administrators (MAICSA) & Member of Dewan Perniagaan Melayu Bandaraya, Kuala Lumpur, Malaysia, Y.M. Tunku Dato’ Mu’tamir Tunku Tan Sri Mohamed; Member of the Negeri Sembilan Royal Household, Y.Bhg Datin Paulene Tunku Mutamir; Member of the Selangor State Legislative Assembly for Kampung Tunku, Y.B Lim Yi Wei; Managing Director of Felement Group, Dato’ Alfred Soh; CEO of ShangHai Media Sdn Bhd, Datin Dr. Cherlin Cheah; Founder Of SBS Group Holdings Bhd, Mr. CM Wong; Co-founder of SBS Group Holdings Bhd, Ms. Elaine Piah; Immediate Past President of SME Malaysia & ShangHai Business Media Honourable Advisor, Datuk Michael Kang and General Manager, Finance and Administration of Hap Seng Star Sdn Bhd & ShangHai Business Media Honourable Advisor, Dato’ Alex C. S. Wong, to grace the ceremony and add brilliance to the event.

In the most beautiful scenes of life, as butterflies adore flowers, women should empower themselves. Dancers gracefully weave through a sea of flowers, resembling butterflies in a dance, marking the commencement of the ceremony. Datin Dr. Cherlin Cheah, in her opening speech, expressed that women play a unique and indispensable role in business. Their wisdom, innovation, and leadership are crucial for constructing a more prosperous and sustainable future. "The SHE 2023 is not just a recognition of women’s achievements but also an encouragement for their transformative contributions in the business arena. "

Y.Bhg Datin Paulene Tunku Mutamir emphasized in her speech, " This grand event serves as a testament to the indomitable spirit, resilience, and unwavering dedication of women who have not just excelled in their chosen industries but have also made profound and meaningful contributions to their communities and beyond. Their leadership, innovation, and inclusive approach have paved the way for positive social change and economic growth. "

The "SHE 2023" awards ceremony gathered outstanding women entrepreneurs from various fields in the Malaysian business community. The winners included notable figures from sports, entertainment, and the music industry, such as the national treasure and renowned songstress YBhg. Dato’ Sri Siti Nurhaliza Tarudin, distinguished actress, host, and singer Dr. Soo Wincci, former women’s badminton player Goh Liu Ying, F V Group founder Vivy Yusof, acclaimed singer Yazmin Aziz, artist and actress Yumi Wong, Miss Malaysia champion and actress Carrie Lee, stylish mom Shaine Wong, actress and model Serene Claire, creating a dazzling array of stars on the stage.

The event also featured special performances by Carrie Lee and Yazmin Aziz captivating the audience with their enchanting melodies. The live music left the guests mesmerized and earned thunderous applause.

The "SHE 2023" features fifteen categories: Lifetime Achievement Noble Woman Award, Outstanding Celebrity Honor Woman Award, Exceptional Woman In Entrepreneurship Award, Motherhood Distinction Award, International Iconic Women Business Award, Outstanding Vocal Achievements Woman Award, Crowning Glory Achievement Award, Professional Woman Of Distinction Award, Pinnacle Of Sportsmanship Woman Award, Distinctive Women Business Award, Outstanding Women Business Award, Prominent Women Business Award, Aspiring Star Women Business Award, Best ESG Women Business Award and International Iconic Women Business Award.

In addition, the conference will also introduce five Honourable recognitions, including the Best Best Impression Recognition, TCHER LYE, LYE BOON ENG – TCHER LYE SDN BHD. Most Inspired Business Model Recognition, SEE TYAN YI – SWEET RENT SDN BHD. Most Resilience Recognition, DATO LEE GAIK CHENG – PUTRA MEDICAL CENTRE. Most Engagement Recognition, LEOH E MUI – JOYRIDE. Best Dress Recognition, YUMI WONG – DE KANGAROO PRODUCTION SDN BHD. The winners of each award was announced live, bringing another wave of excitement to the event.

A warm thank you to the following organizations for their full support – SHE2023’s endorsement partners Shanghai Businesswomen Social Club (SBSC), SME Association of Malaysia (SME), Malaysia Retail Chain Association Women Division (MRCA), Malaysia Chinese Assembly Hall Women Division (MCAH), Business Networking Club Women Division (BNC), ASEAN Retail-Chains & Franchise Federation (ARFF), Asia – Pacific Entrepreneur Associate Chamber of Commerce (APEACC), Branding Association of Malaysia (BAM); the affiliate Partners Felement Group and Big Onion Food Caterer Sdn Bhd; the official health partner, Medicap Sdn Bhd; the official F&B partner, Paradise (F&B) Malaysia Sdn Bhd; the official vehicle tinted partner, Vorra Window Film Malaysia; the brand partners Derm10,Visual Solutions (M) Sdn Bhd, Raffles Homeland Sdn Bhd; the official media partners, NanYang Siang Pau, EightFM, OMNiA, Focus Malaysia; the merchandise sponsors Avelon Healthcare Group and Elleven Lingerie International Sdn Bhd; the gown sponsor, Precious Precious Sdn Bhd; the decoration sponsor, The Jey Enterprise Sdn Bhd; the performance sponsor, Serene Claire and Yazmin Aziz; the lucky draw sponsors, Vtalent Business Sdn Bhd (Joyoung), Avelon Healthcare Sdn Bhd, Ebelle Sdn Bhd, Beauty High Point Sdn Bhd, Epitex International, uchino Marketing (M) Sdn Bhd, Derm 10, Felement, Vorra Window Film Malaysia. The event’s success was also attributed to the support from Aspial Production, and others supporting partners for making the event a great success.

ShangHai Business Media

ShangHai was founded in the year 1979, is the first Chinese Business Magazine Media in Malaysia, which is also the World Oldest Chinese Business Magazine Media. In the year 2018, ShangHai has successfully transformed from traditional printed copy business media into digital business media, aims to provide entrepreneurs with the highest quality and high-end business communication platform.

Source : ShangHai Honourable Women Entrepreneur Business Award 2023 (SHE 2023) Celebrates Outstanding Achievements of Malaysian Women Entrepreneurs

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

To Help Clients Grow and Expand Globally

NEW YORK, Dec. 18, 2023 /PRNewswire/ — On December 18, 2023 – Han Kun Law Offices ("Han Kun" or the "Firm") announced the official opening and operation in New York City of Han Kun LLP ("Han Kun NY"), a New York limited liability partnership established in collaboration with US-based professionals.

Han Kun LLP Opens in New York City to Offer Legal Services

In the wake of Han Kun Singapore office which went into operation in April of this year, Han Kun NY is another strategically important step of the Firm to further expand our global footprint.  The new office represents the Firm’s commitment to strengthen our capabilities to serve our clients’ interest worldwide.  Not only is Han Kun NY a critical mix in the expansion of our global network, but also a requisite platform to better serve the needs of our clients operating overseas.

Han Kun NY is located on the 2nd Floor of the Rockefeller Center, 620 Fifth Avenue, New York City, the United States of America.  The new office will work closely with other US-based professional service providers as well as the Firm’s other offices to meet our clients’ needs in the United States.  We will continue to follow the philosophy of "China Practice, Global Vision" and provide pragmatic, efficient, integrated and quality legal services to our corporate and individual clients and help them implement their global strategies and development in the United States and elsewhere in the world.

About Han Kun
Han Kun is a leading full-service law firm in China.  Over the years, Han Kun has been widely and consistently recognized as a leader in complex cross-border and domestic transactions and compliance matters.  Our main practice areas include private equity, mergers and acquisitions, international and domestic capital markets, investment funds, asset management, compliance, banking and finance, aviation finance, foreign direct investment, antitrust/competition, data protection, private client/wealth management, intellectual property, bankruptcy and restructuring and dispute resolution.  We have over 800 professionals located in Beijing, Shanghai, Shenzhen, Hong Kong, Haikou, Wuhan, Singapore and New York City.

For more information about Han Kun and Han Kun NY, please visit：

Han Kun

Official Website: www.hankunlaw.com
Official WeChat Account: WeChat ID: hankunlaw
Email: [email protected]

Han Kun NY

Email: [email protected]
New York-based Partner: Mike Chiang
Telephone: +1 646 849 2888
Mobile: +1 415 269 5589
Email: [email protected] 

Source : Han Kun LLP Opens in New York City to Offer Legal Services

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Sean O’Neill joins Syncron’s visionary leadership team to oversee the strategic direction, development and execution of the organization’s product and technology initiatives.

STOCKHOLM, Dec. 18, 2023 /PRNewswire/ — Syncron, a global leader in intelligent service lifecycle management solutions that empower leading manufacturers and distributors to capitalize on the world’s new service economy, today announced the appointment of Sean O’Neill as chief product and technology officer, effective immediately.

Sean O’Neill, Chief Product and Technology Officer, Syncron

As CPTO, O’Neill’s mission is to unify all Syncron solutions as a completely integrated set of capabilities for OEMs to manage their equipment-related service businesses in a fully connected way, enhancing end-customer service levels beyond individual best-of-breed solutions.

O’Neill brings over 25 years of experience at the intersection of customer needs, technology and business impact. Before joining Syncron, O’Neill was chief product officer at GfK, where he was instrumental in launching its AI-powered intelligence platform. He has also worked at Amazon, Tesco and various technology startups, generating significant enterprise value across the global technology, consumer and retail sectors. With a proven track record of delivery and a whole-business mindset, O’Neill is passionate about leading with a culture of integrity, action, intellectual honesty and accountability.

"Witnessing the phenomenal success Syncron has achieved thus far and recognizing the vast potential for substantial growth in the years ahead is truly inspiring," said O’Neill. "I am honored to embark on this journey, serving our valued customers, collaborating with our exceptional team and contributing to our goal of making the world a better-serviced place."

The unwavering vision at Syncron is to be at the forefront of technological innovation, driving growth and expansion in the ever-evolving landscape of aftermarket sales and service processes. With an impressive track record fostering innovation, O’Neill is poised to play a pivotal role in steering Syncron toward unprecedented growth, solidifying its position as a leader in aftermarket service management solutions. O’Neill’s strategic insight and commitment to pushing the boundaries of technology align seamlessly with the leadership team’s vision of a future defined by continuous advancement and expansion.

"Sean brings a wealth of experience around businesses capitalizing on data and data insights that will strengthen Syncron’s ability to help OEMs understand and monetize data analytics powered by AI, ML and data lakes. His expertise perfectly complements our vision for innovation and growth," said Dr. Friedrich Neumeyer, CEO, Syncron. "With his addition to the leadership team, we aim to elevate our strategic initiatives and drive Syncron to new heights."

About Syncron 
Syncron helps manufacturers and distributors capitalize on the new service economy by optimizing aftermarket profitability, increasing customer loyalty and enabling the transition to servitization. Syncron aligns all aftermarket services with its Connected Service Experience (CSX) cloud platform, helping companies differentiate themselves through exceptional aftermarket experiences while driving significant revenue growth. The world’s top brands trust Syncron, making it the largest privately-owned global leader in intelligent service lifecycle management SaaS solutions. For more, visit syncron.com.

Source : Syncron Appoints New Chief Product and Technology Officer To Drive Innovation and Growth

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

YANTAI, China, Dec. 18, 2023 /PRNewswire/ — RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, has recently confirmed that under the 2023 simple renewal mechanism of China National Healthcare Security Administration (NHSA), on January 1, 2024, the updated National Reimbursement Drug List (NRDL) will continue to include Telitacicept (RC18) and Disitamab Vedotin (RC48) for the next two-year agreement. This achievement represents a significant milestone for RemeGen in the innovative pharmaceutical industry and reinforces its prominent position in the market. The successful renewal also underscores the effectiveness of RemeGen’s business strategy and highlights positive strides in enhancing the accessibility of innovative drugs within the Chinese market.

"The simplified renewal provides a solid foundation for the sustainable development of innovative drug companies such as RemeGen and allows for the continuous improvement of patient access to innovative drugs, meaning patients can truly benefit from healthcare innovations." said Dr. Jianmin Fang, CEO of RemeGen.

Telitacicept, RemeGen’s proprietary novel fusion protein for the treatment of autoimmune diseases and the world’s first innovative dual-target biological agent for treating systemic lupus erythematosus (SLE), received approval from China’s National Medical Products Administration (NMPA) in March 2021 and subsequently entered the market. By December of the same year, the product was first added to the updated National Reimbursement Drug List (NRDL) to treat adult patients with SLE. Upon conditional marketing approval from the NMPA on March 9, 2021, it received full marketing approval on November 22 this year. The results of the Phase III study of Telitacicept showed the SRI-4 Telitacicept group response rate to be significantly higher than that of the placebo group (82.6% vs 38.1%), with positive effects.

Disitamab Vedotin, an investigational anti-HER2 antibody-drug conjugate targeting prevalent solid cancers with significant unmet medical needs, obtained marketing approval in June and December 2021, respectively, for treating patients with HER2-expressing locally advanced or metastatic gastric cancer (GC) and advanced urothelial cancer (mUC). In December 2021, the HER2-expressing GC indication was successfully included in the updated NRDL. Furthermore, in January 2023, related urothelial cancer indication was also added to the same NRDL.

As per the information presented in RemeGen’s 2022 annual report, the inclusion of Telitacicept and Disitamab Vedotin on the NRDL at the close of 2021 had a substantial impact on product production and sales in 2022. Notably, sales witnessed a remarkable surge, escalating by 1780 percent and 1513 percent for Telitacicept and Disitamab Vedotin, respectively, compared to the preceding year. This not only underscores the effectiveness and growing popularity of these drugs among patients but also signifies a substantial rise in drug demand, attributed to the alleviation of financial burdens on patients through medical insurance.

The successful renewal by RemeGen not only showcases its robust competitiveness in the Chinese market but also mirrors the rapid development of medical care in China while serving as a positive example of China’s pharmaceutical industry on the global stage. Looking ahead, RemeGen is poised to maintain a pivotal role in the global pharmaceutical market.

About RemeGen Co. Ltd.

Founded in 2008, RemeGen (9995.HK, SHA: 688331) is a leading biopharmaceutical company in China committed to providing solutions to the unmet clinical needs of patients suffering from life-threatening illnesses. RemeGen has research laboratories and offices throughout China and the United States. The company is committed to discovering, developing, and commercializing innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune, oncology, and ophthalmic diseases. For more details, please visit: www.remegen.com

About Telitacicept (RC18) 

Telitacicept (RC18) is RemeGen’s proprietary novel fusion protein for the treatments of autoimmune diseases. It is constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor and the fragment crystallizable (Fc) domain of human immunoglobulin G(IgG). Telitacicept targets two cell-signaling molecules critical for B-lymphocyte development: B-lymphocyte stimulator(BLyS) and a proliferation-inducing ligand (APRIL), which allows it to effectively reduce B-cell mediated autoimmune responses that are implicated in several autoimmune diseases. It was granted conditional marketing approval by China’s National Medical Products Administration (NMPA) to treat systemic lupus erythematosus (SLE) in March 2021.

About Disitamab Vedotin (RC48)

Disitamab Vedotin (RC48) is an investigational anti-HER2 antibody-drug conjugate targeting prevalent solid cancers with significant unmet medical needs and is the first domestically developed ADC to receive marketing approval in China. The drug was granted conditional marketing approval in June 2021 by the National Medical Products Administration (NMPA) in China to treat locally advanced or metastatic gastric cancer. In the same month, the company submitted an Investigational New Drug (IND) application for the treatment of HER2-expressing advanced or metastatic urothelial carcinoma with disitamab vedotin. In 2021, RemeGen and Seagen Inc. entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin.

The company is implementing a differentiated development and commercial strategy for disitamab vedotin, including (i) gastric cancer (GC), (ii) urothelial carcinoma (UC), (iii) breast cancer (BC), and (iv) other HER2-expressing cancers.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to RemeGen, are intended to identify certain of such forward-looking statements. RemeGen does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of RemeGen with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond RemeGen’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, RemeGen’s competitive environment and political, economic, legal and social conditions.

RemeGen, the Directors and the employees of RemeGen assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements do not materialize or turn out to be incorrect.

Source : RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network